Douglas Lane & Associates LLC Decreases Stake in GSK PLC Sponsored ADR $GSK

Key Points

• Douglas Lane & Associates LLC reduced its holdings in GSK PLC Sponsored ADR by 13.4%, owning approximately 1.32 million shares valued at $50.58 million.
• GSK recently reported earnings of $1.23 EPS, beating analyst estimates, with a revenue of $10.64 billion, reflecting a 1.3% increase from the previous year.
• The company declared a quarterly dividend of $0.4206, with an annualized yield of 4.1%, despite a payout ratio of 77.78%.

Douglas Lane & Associates LLC lessened its stake in shares of GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 13.4% in the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 1,317,109 shares of the pharmaceutical company's stock after selling 204,417 shares during the period. Douglas Lane & Associates LLC owned 0.06% of GSK worth $50,577,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Kingsview Wealth Management LLC grew its stake in GSK by 1.8% in the first quarter. Kingsview Wealth Management LLC now owns 15,227 shares of the pharmaceutical company's stock worth $590,000 after purchasing an additional 271 shares in the last quarter. Rehmann Capital Advisory Group raised its stake in shares of GSK by 4.6% during the 1st quarter. Rehmann Capital Advisory Group now owns 6,407 shares of the pharmaceutical company's stock valued at $248,000 after buying an additional 279 shares during the last quarter. First PREMIER Bank increased its stake in shares of GSK by 6.5% in the 1st quarter. First PREMIER Bank now owns 4,659 shares of the pharmaceutical company's stock valued at $181,000 after purchasing an additional 286 shares in the last quarter. Northwest Bank & Trust Co increased its stake in GSK by 1.3% during the 4th quarter. Northwest Bank & Trust Co now owns 22,405 shares of the pharmaceutical company's stock worth $765,000 after buying an additional 289 shares in the last quarter. Finally, OneAscent Financial Services LLC boosted its holdings in shares of GSK by 3.9% during the 1st quarter. OneAscent Financial Services LLC now owns 7,700 shares of the pharmaceutical company's stock worth $297,000 after purchasing an additional 292 shares during the last quarter. 15.74% of the stock is currently owned by hedge funds and other institutional investors.

GSK Stock Performance

NYSE:GSK traded up $0.34 on Friday, reaching $40.64. 1,528,795 shares of the company's stock were exchanged, compared to its average volume of 5,004,245. The stock has a fifty day simple moving average of $38.85 and a 200-day simple moving average of $38.53. The company has a debt-to-equity ratio of 1.07, a current ratio of 0.87 and a quick ratio of 0.57. GSK PLC Sponsored ADR has a 52 week low of $31.72 and a 52 week high of $42.63. The firm has a market cap of $82.76 billion, a price-to-earnings ratio of 18.80, a P/E/G ratio of 2.01 and a beta of 0.53.

GSK (NYSE:GSK - Get Free Report) last issued its earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 EPS for the quarter, topping the consensus estimate of $1.12 by $0.11. The company had revenue of $10.64 billion for the quarter, compared to the consensus estimate of $7.92 billion. GSK had a net margin of 10.81% and a return on equity of 49.22%. The firm's revenue for the quarter was up 1.3% on a year-over-year basis. During the same period in the previous year, the firm earned $0.43 earnings per share. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. As a group, sell-side analysts predict that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current year.

GSK Cuts Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 9th. Stockholders of record on Friday, August 15th will be given a dividend of $0.4206 per share. The ex-dividend date of this dividend is Friday, August 15th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 4.1%. GSK's dividend payout ratio is presently 77.78%.

Analyst Ratings Changes

GSK has been the topic of several recent analyst reports. Wall Street Zen raised GSK from a "buy" rating to a "strong-buy" rating in a report on Friday, September 5th. Berenberg Bank reissued a "hold" rating on shares of GSK in a research note on Tuesday, June 3rd. Six investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Reduce" and a consensus price target of $37.38.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.